Serina Therapeutics

Company

Related News

Serina Completes Sentinel Dosing in Cohort 1 of Phase Ib Trial for Parkinson’s

Jul 13, 2026

Serina Therapeutics completes sentinel dosing in Cohort 1 of its Phase Ib registrational trial of SER-252 for advanced Parkinson's disease. Safety review recommends continuation; enrollment and dosing ongoing. FDA alignment on 505(b)(2) pathway and registrational status.

Serina Therapeutics Enrolls First Patient in Phase 1b Trial of SER-252 for Parkinson's Disease

Feb 19, 2026

Serina Therapeutics has enrolled the first patient in its Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease in Australia, with dosing expected to begin in the first quarter of 2026.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07422675	SAD Study in Patients With Parkinson's Disease and Motor Fluctuations	RECRUITING	PHASE1